<DOC>
	<DOCNO>NCT01458106</DOCNO>
	<brief_summary>The primary objective study evaluate safety Recombinant Coagulation Factor VIII Fc Fusion Protein ( rFVIIIFc ) previously treat pediatric subject hemophilia A . Secondary objective study study population follow : evaluate efficacy rFVIIIFc prevention treatment bleed episode ; evaluate ass pharmacokinetics ( PK ) rFVIIIFc ; evaluate rFVIIIFc consumption prevention treatment bleed episode .</brief_summary>
	<brief_title>Study Evaluate Safety , Efficacy , Pharmacokinetics Recombinant Coagulation Factor VIII Fc Fusion Protein ( rFVIIIFc ) Previously Treated Pediatric Subjects With Hemophilia A</brief_title>
	<detailed_description>Previously treat pediatric participant treat prophylactic regimen rFVIIIFc . PK analysis pre-study factor VIII ( FVIII ) rFVIIIFc perform sub-group study participant prior commencement prophylactic treatment . After PK result available , remain participant option proceed directly prophylactic treatment . After complete end study assessment , eligible participant would able continue treatment Study 8HA01EXT .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Key Severe hemophilia A define &lt; 1 IU/dL ( &lt; 1 % ) endogenous FVIII Male &lt; 12 year age weight â‰¥13 kg History least 50 documented prior exposure day FVIII No current , history , inhibitor development FVIII Key Other coagulation disorder addition Hemophilia A History anaphylaxis associate FVIII IV immunoglobulin administration NOTE : Other protocoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>